for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Westlaw News

Celgene to pay Mylan $62 million to resolve cancer drug antitrust case

Mylan NV says Celgene Corp will pay it $62 million to resolve a lawsuit alleging the drugmaker improperly stifled competition for its cancer treatment drugs Thalomid and Revlimid by preventing generic versions from entering the market.

Mylan disclosed the settlement in a filing with the U.S. Securities and Exchange Commission on Monday, days after Celgene agreed to pay $55 million to resolve a related class action lawsuit in federal court in Newark, New Jersey.

To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/2YjMChq

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up